


# GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors



## Authors

David G. DeNardo, Anna Galkin, Jakob Dupont, Lei Zhou, Johanna C. Bendell

## Correspondence

ddenardo@wustl.edu

## In Brief

GB1275 binds CD11b on tumor-associated macrophages (TAMs) and monocytic- and polymorphonuclear-myeloid-derived suppressor cells (mMDSCs and PMN-MDSCs) leading to a shift in polarization to pro-inflammatory phenotypes and an influx of activated CD8<sup>+</sup> T cells. GB1275 induced alterations in the tumor immune infiltrate led to improved response to standard of care and checkpoint blockade in preclinical models and may provide an approach to target MDSC-mediated resistance to immune checkpoint inhibitors in advanced solid tumors.